QBE shrugs off dour market conditions to grow its FY22 net profit by $20m
Nick Sundich, February 17, 2023
QBE (ASX:QBE) managed to grow its FY22 NPAT by $20m in spite of difficult market conditions. It isn’t an easy time to be an insurer, but the company’s premium growth was enough to counter the market.
No time to do stock research, but you still want to invest?
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
QBE records a solid result
QBE’s FY22 NPAT was US$770m, up from US$750m in FY21, and it recorded a 10.5% cash Return on Equity.
The company paid a total dividend of 3c per share, representing a payout ratio of 48% of adjusted cash profit and a 2.9% yield at yesterday’s closing share price.
QBE (ASX:QBE) 1-year share price chart, log scale (Source: TradingView)
Premiums make up for difficult conditions
There were difficult economic conditions during 2022 with heightened inflation, geopolitical tensions, elevated catastrophic activity and poor financial market conditions.
Indeed, QBE recorded an investment loss of $776m after a $122m return in FY21. This was due to unrealised losses associated with the significant increase in bond yields.
However, the insurer’s customers see the need for its service more than ever and were willing to pay more for an additional layer of protection.
The company recorded gross written premium growth of 13% and a groupwide renewal increase of 7.9%.
Looking to FY23, the company promised gross written premium growth of mid to high single digits.
Stocks Down Under Concierge gives you timely BUY and SELL alerts on ASX-listed stocks!
With price targets, buy ranges, stop loss levels and Sell alerts too.
GET A 3-MONTH FREE TRIAL TO CONCIERGE TODAY
No credit card needed and the trial expires automatically.
Blog Categories
Get Our Top 5 ASX Stocks for FY25
Recent Posts
Trump vs. Jerome Powell: What Happens to the Market If Powell Is Fired?
The relationship between President Donald Trump and Federal Reserve Chair Jerome Powell has often been tumultuous, particularly around decisions regarding…
Telix Pharmaceuticals (ASX:TLX): It’s made ~A$1.7bn in revenue from Illucix, but here’s why the best is yet to come!
What would you have thought if you were told 5 years ago you would see Telix Pharmaceuticals as a successful…
Anti Woke ETFs: Do they practice what they preach and have they outperformed since Trump’s return to power?
Have you ever heard of so-called ‘Anti Woke ETFs’? If you’re sick of companies that are big on ESG, this…